Quotient Limited to Report Second Quarter Fiscal Year 2022 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT) has announced that it will release its fiscal second quarter financial results for the period ending September 30, 2021, before the market opens on November 9, 2021. A conference call will take place on the same day at 8:00 a.m. ET to discuss these results. Quotient specializes in transfusion diagnostics, leveraging its MosaiQ technology to enhance laboratory efficiencies. Notably, the MosaiQ COVID-19 Antibody Microarray has received CE marking and FDA Emergency Use Authorization.
- MosaiQ technology improves efficiencies in diagnostics.
- MosaiQ COVID-19 Antibody Microarray has received FDA Emergency Use Authorization.
- None.
JERSEY, Channel Islands, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that financial results for its fiscal second quarter ended September 30, 2021 will be released before market open on Tuesday, November 9, 2021.
Quotient will host a conference call to discuss its second quarter financial results at 8:00 a.m. Eastern Time the same day. Participants may access the call by dialing 1-877-407-0784 in the U.S. or 1-201-689-8560 outside the U.S. The access code is 13724411. The conference call will be webcast live on the Company's website at www.quotientbd.com.
A replay of this conference call will be available through November 16, 2021 by dialing 1-844-512-2921 in the U.S. or 1-412-317-6671 outside the U.S. The replay access code is 13724411.
About Quotient Limited
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.
The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
Contact: IR@quotientbd.com; +41 22 545 52 26
FAQ
When will Quotient Limited release its fiscal second quarter results for 2021?
What is the focus of Quotient Limited's conference call on November 9, 2021?
What technology does Quotient Limited use for diagnostics?
Has Quotient Limited's COVID-19 testing technology received any regulatory approvals?
